debrisoquin has been researched along with Liver Diseases in 4 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mephenytoin metabolism was significantly decreased in both patients with mild liver disease (Child-Pugh score of 5/6) (-63% [95% confidence interval (CI), -86% to -40%]; P = ." | 2.72 | Liver disease selectively modulates cytochrome P450--mediated metabolism. ( Branch, RA; Chaves-Gnecco, D; Frye, RF; Matzke, GR; Rabinovitz, M; Shaikh, OS; Zgheib, NK, 2006) |
| " As a consequence, alteration in metabolism of specific drugs cannot be easily predicted or appropriate dosage adjustment recommendations made." | 2.69 | Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6. ( Adedoyin, A; Arns, PA; Branch, RA; Richards, WO; Wilkinson, GR, 1998) |
| "Perhexiline maleate is an antianginal agent which depends on hepatic oxidation for its elimination." | 1.27 | Impaired oxidation of debrisoquine in patients with perhexiline liver injury. ( Morgan, MY; Oates, NS; Reshef, R; Shah, RR; Sherlock, S; Smith, RL, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dorne, JL | 1 |
| Walton, K | 1 |
| Slob, W | 1 |
| Renwick, AG | 1 |
| Frye, RF | 1 |
| Zgheib, NK | 1 |
| Matzke, GR | 1 |
| Chaves-Gnecco, D | 1 |
| Rabinovitz, M | 1 |
| Shaikh, OS | 1 |
| Branch, RA | 2 |
| Morgan, MY | 1 |
| Reshef, R | 1 |
| Shah, RR | 1 |
| Oates, NS | 1 |
| Smith, RL | 1 |
| Sherlock, S | 1 |
| Adedoyin, A | 1 |
| Arns, PA | 1 |
| Richards, WO | 1 |
| Wilkinson, GR | 1 |
2 trials available for debrisoquin and Liver Diseases
| Article | Year |
|---|---|
Liver disease selectively modulates cytochrome P450--mediated metabolism.
Topics: Administration, Oral; Adult; Anticonvulsants; Antihypertensive Agents; Caffeine; Case-Control Studie | 2006 |
Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Topics: Adult; Aged; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P- | 1998 |
2 other studies available for debrisoquin and Liver Diseases
| Article | Year |
|---|---|
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoqu | 2002 |
Impaired oxidation of debrisoquine in patients with perhexiline liver injury.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Chemical and Drug Induced Liver Injury; Chronic Disease; D | 1984 |